Research

LIke ThisLIke ThisLIke This

David  Briscoe, MB, ChB

david-briscoe
Research Center:
Transplant Research Program
Division
Nephrology Research
Hospital Title:
Director, Transplant Research Program and Fellowship Program
Academic Title:
Associate Professor of Medicine, Harvard Medical School
Research Focus Area:
Transplant rejection
Contact:
617-919-2992
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

About David Briscoe

Dr. David Briscoe is an Associate Professor of Pediatrics at Harvard Medical School and the Casey Lee Ball Chair in Transplantation at Boston Children's Hospital. He trained in Pediatrics, Nephrology and transplantation immunology, and directs a research program focused on the understanding of chronic allograft rejection with a goal to enhance long-term outcomes following solid organ transplantation.

Dr. Briscoe earned his medical degree at the Royal College of Surgeons in Ireland and performed his initial residency training in General Medicine and Pediatrics in Dublin. He also completed Pediatric Residency training at the University of Colorado Health Sciences Center in Denver, Colorado, and a postdoctoral fellowship in Pediatric Nephrology at Boston Children’s Hospital and Harvard Medical School. Among several honors, Dr. Briscoe was awarded a Young Investigator Award and the Basic Science Investigator Award of the American Society of Transplantation. He was also elected to the national honors society, the American Society of Clinical Investigation in 2004. In 2008, Dr. Briscoe became the Fellowship Program Director in Pediatric Nephrology at Boston Children's Hospital and Principal Investigator of a T32 training program grant. In 2013, he was appointed Director of the Transplant Research Program at Boston Children’s Hospital, and in 2015, he became the first incumbent Casey Lee Ball Chair in Transplantation.

Dr. Briscoe belongs to a number of Professional Societies, including the Pediatric Academic Societies, the American Society of Transplantation, the American Society of Transplant Surgeons and the American Society of Nephrology. He has held leadership positions, both national and international, including being a member of the Board of Directors of the American Society of Transplantation, the Executive Committee Chair for the American Transplant Congress, Program Chair in Immunology for the Annual Meeting of the American Society of Nephrology and Chair of the Public Policy Committee for the American Society of Transplantation. Currently, Dr. Briscoe serves as a Councilor for the International Pediatric Transplant Association, an affiliate of the Transplantation Society. In these positions, Dr. Briscoe has been a strong advocate for pediatric transplant recipients, and he is most supportive of discovery-based research, translational research and clinical trials in the field to impact long-term care. He is also a strong advocate for the training of physicians and scientists in biomedical research.

Dr. Briscoe’s research focuses on endothelial immunobiology and immune-mediated angiogenesis as underlying mechanisms in chronic allograft rejection. He has held several NIH R01 grants, a program project grant, and he has been involved in multicenter clinical trials to advance biomarker development and translational research initiatives.  He also serves as a standing member on a NIH study section and is a regular reviewer on special grant review committees to provide transplant expertise. He has also served on the editorial board of several transplant journals and is currently the senior editor of Transplantation Direct.

For more about Dr. Briscoe’s research, please visit www.briscoelab.com

Key Publications

View Dr.Briscoe’s publications in PubMed.

Publications

Publications powered by Harvard Catalyst Profiles
  1. Boneschansker L, Nakayama H, Eisenga M, Wedel J, Klagsbrun M, Irimia D, Briscoe DM. Netrin-1 Augments Chemokinesis in CD4+ T Cells In Vitro and Elicits a Proinflammatory Response In Vivo. J Immunol. 2016 Aug 15; 197(4):1389-98.
  2. Jain NG, Wong EA, Aranyosi AJ, Boneschansker L, Markmann JF, Briscoe DM, Irimia D. Microfluidic mazes to characterize T-cell exploration patterns following activation in vitro. Integr Biol (Camb). 2015 Nov; 7(11):1423-31.
  3. Starling RC, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, Morrison Y, Bridges ND, Putheti P, Strom TB, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly KP, Briscoe DM, Heeger PS. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. Am J Transplant. 2016 Jan; 16(1):121-36.
  4. Bruneau S, Wedel J, Fakhouri F, Nakayama H, Boneschansker L, Irimia D, Daly KP, Briscoe DM. Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. Pediatr Nephrol. 2016 Jan; 31(1):41-51.
  5. Wedel J, Bruneau S, Kochupurakkal N, Boneschansker L, Briscoe DM. Chronic allograft rejection: a fresh look. Curr Opin Organ Transplant. 2015 Feb; 20(1):13-20.
  6. Boneschansker L, Yan J, Wong E, Briscoe DM, Irimia D. Microfluidic platform for the quantitative analysis of leukocyte migration signatures. Nat Commun. 2014 Sep 03; 5:4787.
  7. Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM, Später D, Xu H, Tabebordbar M, Gorbatov R, Sena B, Nahrendorf M, Briscoe DM, Li RA, Wagers AJ, Rossi DJ, Pu WT, Chien KR. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013 Oct; 31(10):898-907.
  8. Bruneau S, Nakayama H, Woda CB, Flynn EA, Briscoe DM. DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood. 2013 Sep 5; 122(10):1833-42.
  9. Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM, Karumanchi SA, Briscoe DM. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2013 Jan; 32(1):120-8.
  10. Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, Dormond O, Briscoe DM, Datta D. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev. 2013 Feb; 24(1):41-9.
  11. Show all
  12. Hoerning A, Köhler S, Jun C, Tebbe B, Fu J, Menke J, Wilde B, Dolff S, Feldkamp T, Briscoe DM, Kribben A, Hoyer PF, Witzke O. Peripherally circulating CD4? FOXP3? CXCR3? T regulatory cells correlate with renal allograft function. Scand J Immunol. 2012 Sep; 76(3):320-8.
  13. Dormond O, Dufour M, Seto T, Bruneau S, Briscoe DM. Targeting the intragraft microenvironment and the development of chronic allograft rejection. Hum Immunol. 2012 Dec; 73(12):1261-8.
  14. McMahon GM, Datta D, Bruneau S, Kann M, Khalid M, Ho J, Seto T, Kreidberg JA, Stillman IE, Briscoe DM. Constitutive activation of the mTOR signaling pathway within the normal glomerulus. Biochem Biophys Res Commun. 2012 Aug 24; 425(2):244-9.
  15. Samsonov D, Geehan C, Woda CB, Briscoe DM. Differential activation of human T cells to allogeneic endothelial cells, epithelial cells and fibroblasts in vitro. Transplant Res. 2012 Apr 24; 1(1):4.
  16. Bruneau S, Woda CB, Daly KP, Boneschansker L, Jain NG, Kochupurakkal N, Contreras AG, Seto T, Briscoe DM. Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation. Front Immunol. 2012; 3:54.
  17. Hoerning A, Koss K, Datta D, Boneschansker L, Jones CN, Wong IY, Irimia D, Calzadilla K, Benitez F, Hoyer PF, Harmon WE, Briscoe DM. Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3. Eur J Immunol. 2011 Aug; 41(8):2291-302.
  18. Evans RW, Applegate WH, Briscoe DM, Cohen DJ, Rorick CC, Murphy BT, Madsen JC. Cost-related immunosuppressive medication nonadherence among kidney transplant recipients. Clin J Am Soc Nephrol. 2010 Dec; 5(12):2323-8.
  19. Datta D, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, Pal S. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res. 2009 Dec 1; 69(23):8902-9.
  20. Contreras AG, Dormond O, Edelbauer M, Calzadilla K, Hoerning A, Pal S, Briscoe DM. mTOR-understanding the clinical effects. Transplant Proc. 2008 Dec; 40(10 Suppl):S9-S12.
  21. Datta D, Contreras AG, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J Am Soc Nephrol. 2008 Dec; 19(12):2437-46.
  22. Briscoe DM, Pal S. Assessing the vascular effects of early erythropoietin use in pediatric renal transplant recipients. Nat Clin Pract Nephrol. 2008 Mar; 4(3):136-7.
  23. Contreras AG, Briscoe DM. Every allograft needs a silver lining. J Clin Invest. 2007 Dec; 117(12):3645-8.
  24. Haskova Z, Izawa A, Contreras AG, Flynn E, Boulday G, Briscoe DM. Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation. 2007 Jun 27; 83(12):1595-601.
  25. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res. 2006 Oct 1; 66(19):9509-18.
  26. Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol. 2006 Mar 1; 176(5):3098-107.
  27. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol. 2006 Apr; 17(4):932-42.
  28. Laxmanan S, Robertson SW, Wang E, Lau JS, Briscoe DM, Mukhopadhyay D. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun. 2005 Aug 19; 334(1):193-8.
  29. Ke B, Shen XD, Gao F, Tsuchihashi S, Farmer DG, Briscoe D, Busuttil RW, Kupiec-Weglinski JW. The CD154-CD40 T-cell co-stimulation pathway in liver ischemia and reperfusion inflammatory responses. Transplantation. 2005 May 15; 79(9):1078-83.
  30. Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol. 2004 Jun 15; 172(12):7503-9.
  31. Tejani A, Alexander S, Ettenger R, Lerner G, Zimmerman J, Kohaut E, Briscoe DM. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant. 2004 Apr; 8(2):151-60.
  32. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay D, Koss KE, Geehan CS, Luster AD, Sayegh MH, Briscoe DM. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest. 2003 Dec; 112(11):1655-65.
  33. Reinders ME, Sho M, Robertson SW, Geehan CS, Briscoe DM. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol. 2003 Aug 1; 171(3):1534-41.
  34. Reinders ME, Fang JC, Wong W, Ganz P, Briscoe DM. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation. 2003 Jul 15; 76(1):224-30.
  35. Vos IH, Briscoe DM. Endothelial injury: cause and effect of alloimmune inflammation. Transpl Infect Dis. 2002 Sep; 4(3):152-9.
  36. Briscoe DM, Sayegh MH. A rendezvous before rejection: where do T cells meet transplant antigens? Nat Med. 2002 Mar; 8(3):220-2.
  37. Lapchak PH, Briscoe DM. Hyporesponsiveness in pediatric recipients. Pediatr Transplant. 2002 Feb; 6(1):8-11.
  38. Melter M, Exeni A, Reinders ME, Fang JC, McMahon G, Ganz P, Hancock WW, Briscoe DM. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation. 2001 Nov 20; 104(21):2558-64.
  39. Sho M, Samsonov DV, Briscoe DM. Immunologic targets for currently available immunosuppressive agents: what is the optimal approach for children? Semin Nephrol. 2001 Sep; 21(5):508-20.
  40. Wood EG, Hand M, Briscoe DM, Donaldson LA, Yiu V, Harley FL, Warady BA, Ellis EN. Risk factors for mortality in infants and young children on dialysis. Am J Kidney Dis. 2001 Mar; 37(3):573-9.
  41. Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol. 2001 Feb 15; 166(4):2451-9.
  42. Abecassis M, Adams M, Adams P, Arnold RM, Atkins CR, Barr ML, Bennett WM, Bia M, Briscoe DM, Burdick J, Corry RJ, Davis J, Delmonico FL, Gaston RS, Harmon W, Jacobs CL, Kahn J, Leichtman A, Miller C, Moss D, Newmann JM, Rosen LS, Siminoff L, Spital A, Starnes VA, Thomas C, Tyler LS, Williams L, Wright FH, Youngner S. Consensus statement on the live organ donor. JAMA. 2000 Dec 13; 284(22):2919-26.
  43. Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD, Mukhopadhyay D, Briscoe DM. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000 Dec 1; 96(12):3801-8.
  44. Denton MD, Davis SF, Baum MA, Melter M, Reinders ME, Exeni A, Samsonov DV, Fang J, Ganz P, Briscoe DM. The role of the graft endothelium in transplant rejection: evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection. Pediatr Transplant. 2000 Nov; 4(4):252-60.
  45. Melter M, Briscoe DM. Challenges after pediatric transplantation. Semin Nephrol. 2000 Mar; 20(2):199-208.
  46. Briscoe D, Adair CF, Thompson LD, Tellado MV, Buckner SB, Rosenthal DL, O'Leary TJ. Telecytologic diagnosis of breast fine needle aspiration biopsies. Intraobserver concordance. Acta Cytol. 2000 Mar-Apr; 44(2):175-80.
  47. Denton MD, Geehan CS, Alexander SI, Sayegh MH, Briscoe DM. Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4(+) T cell alloactivation. J Exp Med. 1999 Aug 16; 190(4):555-66.
  48. Briscoe DM, Dharnidharka VR, Isaacs C, Downing G, Prosky S, Shaw P, Parenteau NL, Hardin-Young J. The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection. Transplantation. 1999 Jun 27; 67(12):1590-9.
  49. Moulton KS, Melder RJ, Dharnidharka VR, Hardin-Young J, Jain RK, Briscoe DM. Angiogenesis in the huPBL-SCID model of human transplant rejection. Transplantation. 1999 Jun 27; 67(12):1626-31.
  50. Melter M, McMahon G, Fang J, Ganz P, Briscoe DM. Current understanding of chemokine involvement in allograft transplantation. Pediatr Transplant. 1999 Feb; 3(1):10-21.
  51. Briscoe DM, Alexander SI, Lichtman AH. Interactions between T lymphocytes and endothelial cells in allograft rejection. Curr Opin Immunol. 1998 Oct; 10(5):525-31.
  52. Davis ID, Bunchman TE, Grimm PC, Benfield MR, Briscoe DM, Harmon WE, Alexander SR, Avner ED. Pediatric renal transplantation: indications and special considerations. A position paper from the Pediatric Committee of the American Society of Transplant Physicians. Pediatr Transplant. 1998 May; 2(2):117-29.
  53. Denton MD, Reul RM, Dharnidharka VR, Fang JC, Ganz P, Briscoe DM. Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection. Pediatr Transplant. 1998 Feb; 2(1):6-15.
  54. Reul RM, Fang JC, Denton MD, Geehan C, Long C, Mitchell RN, Ganz P, Briscoe DM. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation. 1997 Dec 27; 64(12):1765-74.
  55. Briscoe DM, Henault LE, Geehan C, Alexander SI, Lichtman AH. Human endothelial cell costimulation of T cell IFN-gamma production. J Immunol. 1997 Oct 1; 159(7):3247-56.
  56. Briscoe DM, Ganz P, Alexander SI, Melder RJ, Jain RK, Cotran RS, Lichtman AH. The problem of chronic rejection: influence of leukocyte-endothelial interactions. Kidney Int Suppl. 1997 Mar; 58:S22-7.
  57. Munro JM, Briscoe DM, Tedder TF. Differential regulation of leucocyte L-selectin (CD62L) expression in normal lymphoid and inflamed extralymphoid tissues. J Clin Pathol. 1996 Sep; 49(9):721-7.
  58. Burns SA, DeGuzman BJ, Newburger JW, Mayer JE, Neufeld EJ, Briscoe DM. P-selectin expression in myocardium of children undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1995 Oct; 110(4 Pt 1):924-33.
  59. Briscoe DM, DesRoches LE, Kiely JM, Lederer JA, Lichtman AH. Antigen-dependent activation of T helper cell subsets by endothelium. Transplantation. 1995 Jun 15; 59(11):1638-41.
  60. Briscoe DM, Yeung AC, Schoen FJ, Allred EN, Stavrakis G, Ganz P, Cotran RS, Pober JS, Schoen EL. Predictive value of inducible endothelial cell adhesion molecule expression for acute rejection of human cardiac allografts. Transplantation. 1995 Jan 27; 59(2):204-11.
  61. Paredes A, Briscoe DM, Williams CK, Garcia-Perez A, Wade JB, Harris HW. Water channel vesicles from toad urinary bladder contain a family of proteins present in other tissues. Am J Physiol. 1994 May; 266(5 Pt 1):C1366-75.
  62. Briscoe DM, Cotran RS. Role of leukocyte-endothelial cell adhesion molecules in renal inflammation: in vitro and in vivo studies. Kidney Int Suppl. 1993 Jul; 42:S27-34.
  63. Rosenblum ND, Briscoe DM, Karnovsky MJ, Olsen BR. Alpha 1-VIII collagen is expressed in the rat glomerulus and in resident glomerular cells. Am J Physiol. 1993 Jun; 264(6 Pt 2):F1003-10.
  64. Briscoe DM, Pober JS, Harmon WE, Cotran RS. Expression of vascular cell adhesion molecule-1 in human renal allografts. J Am Soc Nephrol. 1992 Nov; 3(5):1180-5.
  65. Briscoe DM, Cotran RS, Pober JS. Effects of tumor necrosis factor, lipopolysaccharide, and IL-4 on the expression of vascular cell adhesion molecule-1 in vivo. Correlation with CD3+ T cell infiltration. J Immunol. 1992 Nov 1; 149(9):2954-60.
  66. Briscoe DM, Kim MS, Lillehei C, Eraklis AJ, Levey RH, Harmon WE. Outcome of renal transplantation in children less than two years of age. Kidney Int. 1992 Sep; 42(3):657-62.
  67. Ford DM, Briscoe DM, Shanley PF, Lum GM. Childhood membranoproliferative glomerulonephritis type I: limited steroid therapy. Kidney Int. 1992 Jun; 41(6):1606-12.
  68. Briscoe DM, Schoen FJ, Rice GE, Bevilacqua MP, Ganz P, Pober JS. Induced expression of endothelial-leukocyte adhesion molecules in human cardiac allografts. Transplantation. 1991 Feb; 51(2):537-9.
  69. Raftos DA, Briscoe DA, Tait NN. The mode of recognition of allogeneic tissue in the solitary urochordate Styela plicata. Transplantation. 1988 Jun; 45(6):1123-6.
  70. Briscoe DM, McMenamin JB, O'Donohoe NV. Prognosis in Guillain-Barré syndrome. Arch Dis Child. 1987 Jul; 62(7):733-5.
  71. Raison RL, Walker KZ, Halnan CR, Briscoe D, Basten A. Loss of secretion in mouse-human hybrids need not be due to the loss of a structural gene. J Exp Med. 1982 Nov 1; 156(5):1380-9.
  72. Briscoe DM, Hoffer FA, Tu N, Harmon WE. Duplex Doppler examination of renal allografts in children: correlation between renal blood flow and clinical findings. Pediatr Radiol. 1993; 23(5):365-8.
  73. Dormond O, Madsen JC, Briscoe DM. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem. 2007 Aug 10; 282(32):23679-86.
  74. Tsuchihashi S, Ke B, Kaldas F, Flynn E, Busuttil RW, Briscoe DM, Kupiec-Weglinski JW. Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am J Pathol. 2006 Feb; 168(2):695-705.
  75. Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, Calzadilla K, Pal S, Briscoe DM. Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol. 2010 Jan 15; 184(2):545-9.
  76. Lapchak PH, Melter M, Pal S, Flaxenburg JA, Geehan C, Frank MH, Mukhopadhyay D, Briscoe DM. CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island. Am J Physiol Renal Physiol. 2004 Sep; 287(3):F512-20.
  77. Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, Briscoe DM. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol. 2008 Dec 1; 181(11):8088-95.
  78. Sho M, Akashi S, Kanehiro H, Hamada K, Kashizuka H, Ikeda N, Nomi T, Kuzumoto Y, Tsurui Y, Yoshiji H, Wu Y, Hicklin DJ, Briscoe DM, Nakajima Y. Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo. Transplantation. 2005 Sep 27; 80(6):717-22.
  79. Edelbauer M, Datta D, Vos IH, Basu A, Stack MP, Reinders ME, Sho M, Calzadilla K, Ganz P, Briscoe DM. Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. Blood. 2010 Sep 16; 116(11):1980-9.
  80. Denton MD, Magee C, Melter M, Dharnidharka VR, Sayegh MH, Briscoe DM. TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy. Transplantation. 2004 Oct 27; 78(8):1218-21.
  81. Basu A, Contreras AG, Datta D, Flynn E, Zeng L, Cohen HT, Briscoe DM, Pal S. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res. 2008 Jul 15; 68(14):5689-98.
  82. Samsonov D, Briscoe DM. Long-term care of pediatric renal transplant patients: from bench to bedside. Curr Opin Pediatr. 2002 Apr; 14(2):205-10.
  83. Laxmanan S, Datta D, Geehan C, Briscoe DM, Pal S. CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol. 2005 Sep; 16(9):2714-23.
  84. Bruneau S, Datta D, Flaxenburg JA, Pal S, Briscoe DM. TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor. Biochem Biophys Res Commun. 2012 Mar 2; 419(1):66-71.
  85. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006 Aug; 10(2):159-70.
  86. Datta D, Dormond O, Basu A, Briscoe DM, Pal S. Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2007 Oct; 293(4):F1222-30.
  87. Nakayama H, Bruneau S, Kochupurakkal N, Coma S, Briscoe DM, Klagsbrun M. Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo. Sci Rep. 2015 Jul 09; 5:11789.
  88. Daly KP, Dearling JL, Seto T, Dunning P, Fahey F, Packard AB, Briscoe DM. Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection. Transplantation. 2015 Sep; 99(9):e132-9.
  89. Pendse SS, Briscoe DM, Frank MH. P-glycoprotein and alloimmune T-cell activation. Clin Appl Immunol Rev. 2003 Jul; 4(1):3-14.
  90. Daly KP, Stack M, Eisenga MF, Keane JF, Zurakowski D, Blume ED, Briscoe DM. Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients. J Heart Lung Transplant. 2016 Oct 3.
  91. Javaheri A, Molina M, Zamani P, Rodrigues A, Novak E, Chambers S, Stutman P, Maslanek W, Williams M, Lilly SM, Heeger P, Sayegh MH, Chandraker A, Briscoe DM, Daly KP, Starling R, Ikle D, Christie J, Rame JE, Goldberg LR, Billheimer J, Rader DJ. Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2016 Nov; 35(11):1295-1302.
  92. Kaplan DM, Briscoe D, Gatot A, Niv A, Leiberman A, Fliss DM. The use of standardized orbital ultrasound in the diagnosis of sinus induced infections of the orbit in children: a preliminary report. Int J Pediatr Otorhinolaryngol. 1999 May 5; 48(2):155-62.
LIke ThisLIke ThisLIke This

RELATED RESEARCH CENTER

Transplant Research Program


Learn more
Close